WAWan-Atirah Azemin

Wan-Atirah Azemin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wan-Atirah Azemin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual-Spectrum Antimicrobial Nylon for Healthcare: Pandanus amaryllifolius Silver Nanoparticles Combat ESKAPK Pathogens and Fungal Infections

    by Hajar Hassan, Iwani Maisarah Norizham, Masratul Hawa Mohd, Noraziah Mohamad Zin, Yazmin Bustami, Wan-Atirah Azemin


  • Open Access

    Fish-derived hepcidins in cancer treatment: a scoping review

    by Wan-Atirah Azemin, Syarifah Ab Rashid, Noraini Philip, Abdul Manaf Ali, Mohd Shahir Shamsir

    Background: The discovery of hepcidin, a peptide hormone primarily known for iron homeostasis regulation, has revealed promising anticancer properties. While extensively studied in mammals, fish-derived hepcidins represent an unexplored area in cancer therapeutics, offering unique structural and functional characteristics that may prove valuable in oncological applications. Method: A scoping review was conducted using the Scopus, Web of Science (WoS), and PubMed databases to comprehensively analyse published literature on fish-derived hepcidins. Publications were identified using Boolean combinations of ‘fish’, ‘hepcidin’, and ‘cancer’. Two independent reviewers screened articles, with a third reviewer resolving disagreements. Research themes were categorised and analysed with focus on species distribution, mechanisms of action, and therapeutic potential. Result: Analysis of 881 publications revealed research distribution across four main categories: immune response (60.07%), antimicrobial peptides (17.65%), iron homeostasis (13.69%), and cancer research (2.94%). The review identified 17 fish species with documented hepcidin studies. Tilapia-derived hepcidins demonstrated notable anticancer properties, including concentration-dependent effects, selective cytotoxicity against cancer cells, and potential enhancement of conventional chemotherapy efficacy through mechanisms involving reactive oxygen species production and mitochondrial apoptosis pathways. Conclusion: Despite promising anticancer properties of fish-derived hepcidins, particularly from tilapia, significant knowledge gaps exist in understanding their cancer-specific mechanisms and clinical applications. Future research should prioritise broader species investigation, safety profiling, and delivery system development to advance their therapeutic potential in cancer treatment.


  • Green-Synthesised Silver Nanoparticles from Pandan Extract: Enhancing PPE Effectiveness and Sustainability in the Post-COVID Era

    by Hajar Hassan, Mohammed Al-Kassim Hassan, Masratul Hawa Mohd, Yazmin Bustami, Noraziah Mohamad Zin, Wan-Atirah Azemin


  • Open Access

    Riding the wave of innovation: immunoinformatics in fish disease control

    by Siti Aisyah Razali, Mohd Shahir Shamsir, Nur Farahin Ishak, Chen-Fei Low, Wan-Atirah Azemin

    The spread of infectious illnesses has been a significant factor restricting aquaculture production. To maximise aquatic animal health, vaccination tactics are very successful and cost-efficient for protecting fish and aquaculture animals against many disease pathogens. However, due to the increasing number of immunological cases and their complexity, it is impossible to manage, analyse, visualise, and interpret such data without the assistance of advanced computational techniques. Hence, the use of immunoinformatics tools is crucial, as they not only facilitate the management of massive amounts of data but also greatly contribute to the creation of fresh hypotheses regarding immune responses. In recent years, advances in biotechnology and immunoinformatics have opened up new research avenues for generating novel vaccines and enhancing existing vaccinations against outbreaks of infectious illnesses, thereby reducing aquaculture losses. This review focuses on understanding in silico epitope-based vaccine design, the creation of multi-epitope vaccines, the molecular interaction of immunogenic vaccines, and the application of immunoinformatics in fish disease based on the frequency of their application and reliable results. It is believed that it can bridge the gap between experimental and computational approaches and reduce the need for experimental research, so that only wet laboratory testing integrated with in silico techniques may yield highly promising results and be useful for the development of vaccines for fish.


  • In silico analysis prediction of HepTH1-5 as a potential therapeutic agent by targeting tumour suppressor protein networks

    by Wan-Atirah Azemin, Nadiawati Alias, Abdul Manaf Ali, Mohd Shahir Shamsir

    Many studies reported that the activation of tumour suppressor protein, p53 induced the human hepcidin expression. However, its expression decreased when p53 was silenced in human hepatoma cells. Contrary to Tilapia hepcidin TH1-5, HepTH1-5 was previously reported to trigger the p53 activation through the molecular docking approach. The INhibitor of Growth (ING) family members are also shown to directly interact with p53 and promote cell cycle arrest, senescence, apoptosis and participate in DNA replication and DNA damage responses to suppress the tumour initiation and progression. However, the interrelation between INGs and HepTH1-5 remains unknown. Therefore, this study aims to identify the mechanism and their protein interactions using in silico approaches. The finding revealed that HepTH1-5 and its ligands had interacted mostly on hotspot residues of ING proteins which involved in histone modifications via acetylation, phosphorylation, and methylation. This proves that HepTH1-5 might implicate in an apoptosis signalling pathway and preserve the protein structure and function of INGs by reducing the perturbation of histone binding upon oxidative stress response. This study would provide theoretical guidance for the design and experimental studies to decipher the role of HepTH1-5 as a potential therapeutic agent for cancer therapy. Communicated by Ramaswamy H. Sarma


  • Structural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement

    by Wan-Atirah Azemin, Nadiawati Alias, Abdul Manaf Ali, Mohd Shahir Shamsir

    Hepcidin is a principal regulator of iron homeostasis and its dysregulation has been recognised as a causative factor in cancers and iron disorders. The strategy of manipulating the presence of hepcidin peptide has been used for cancer treatment. However, this has demonstrated poor efficiency and has been short-lived in patients. Many studies reported using minihepcidin therapy as an alternative way to treat hepcidin dysregulation, but this was only applied to non-cancer patients. Highly conserved fish hepcidin protein, HepTH1-5, was investigated to determine its potential use in developing a hepcidin replacement for human hepcidin (Hepc25) and as a therapeutic agent by targeting the tumour suppressor protein, p53, through structure-function analysis. The authors found that HepTH1-5 is stably bound to ferroportin, compared to Hepc25, by triggering the ferroportin internalisation via Lys42 and Lys270 ubiquitination, in a similar manner to the Hepc25 activity. Moreover, the residues Ile24 and Gly24, along with copper and zinc ligands, interacted with similar residues, Lys24 and Asp1 of Hepc25, respectively, showing that those molecules are crucial to the hepcidin replacement strategy. HepTH1-5 interacts with p53 and activates its function through phosphorylation. This finding shows that HepTH1-5 might be involved in the apoptosis signalling pathway upon a DNA damage response. This study will be very helpful for understanding the mechanism of the hepcidin replacement and providing insights into the HepTH1-5 peptide as a new target for hepcidin and cancer therapeutics. Communicated by Ramaswamy H. Sarma